NS 2028

Key Product Details

Product Description

NS 2028 is a potent soluble guanylyl cyclase (sGC) inhibitor (K_i = 8 nM). Blocks sGC activity in murine cerebellum induced by S-nitroso-glutathione and NMDA (IC₅₀ values are 17 and 20 nM respectively). Inhibits VEGF-induced cGMP accumulation; abolishes VEGF-induced migration in postcapillary venular endothelial cells (CVEC).

Product Specifications for NS 2028

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for NS 2028

The following data is based on the product molecular weight 269.05.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.72 mL	18.58 mL	37.17 mL
5 mM	0.74 mL	3.72 mL	7.43 mL
10 mM	0.37 mL	1.86 mL	3.72 mL
50 mM	0.07 mL	0.37 mL	0.74 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 7 publications citing the usage of this product.

• Morbidelli The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability. Am.J.Physiol.Regul.Integr.Comp.Physiol. 2010 PMID: 20032260
• Olesen Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Br.J.Pharmacol. 1998 PMID: 9489619
• von Wantoch Rekowski Synthesis and biological evaluation of oxadiazole derivatives as inhibitors of soluble guanylyl cyclase. Bioorg.Med.Chem. 2010 PMID: 20036129

Product Documents for NS 2028